Drilldown: Medicines
Appearance
Medicines > classes:
[[:Category:Antihypertensives|Antihypertensive]]
& fda max
:
320 mg/d (hypertension); 320 mg/d (HF)
or
40 mg/d 
& fda max
:
320 mg/d (hypertension); 320 mg/d (HF)
or
40 mg/d 
Use the filters below to narrow your results.
None (2) ·
'"`UNIQ--vote-000004C8-QINU`"' Largely hepatically cleared (~80% biliary); no active metabolite. Sacubitril-valsartan (Entresto) combines an ARB with neprilysin inhibition for HFrEF and was a notable advance over the ARB-alone trial (PARADIGM-HF, 2014)'"`UNIQ--ref-000004C9-QINU`"'. (1)
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection'"`UNIQ--ref-000004CF-QINU`"' (1) ·
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection'"`UNIQ--ref-0000056E-QINU`"' (1) ·
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, skull hypoplasia, hypotension. Stop on detection'"`UNIQ--ref-00000B86-QINU`"' (1)
Showing below up to 3 results in range #1 to #3.

